Two of the most anticipated studies this year—large-scale, randomized, controlled, and double-blinded trials of the popular obesity and diabetes drug semaglutide for Alzheimer’s disease—have unfortunately ended in a dud.

Novo Nordisk, the makers of semaglutide, announced the disappointing trial results early Monday morning. The drug did not meaningfully slow down the disease’s progression compared to placebo, the trials showed. The company will now shut down the extension of these trials, though some experts and advocacy groups are still hopeful about the potential future of GLP-1 therapy for Alzheimer’s.

“While these results are not what we had hoped for, they will contribute to our understanding of this devastating and fatal disease,” said Joanne Pike, president and chief executive o

See Full Page